Chikungunya Vaccine IXCHIQ: Expansion to Adolescents in Europe and Canada
Chikungunya Vaccine IXCHIQ Expansion
Valneva SE (VALN) has announced the submission of label extension applications to the European Medicines Agency (EMA) and Health Canada. The aim is to expand the use of their chikungunya vaccine, IXCHIQ, to adolescents aged 12 to 17 years in Europe and Canada. This initiative seeks to address the rising need for preventative measures against the chikungunya virus among younger populations.
Applications Overview
- EMA Application: Tailored for European markets, focusing on adolescent safety and efficacy.
- Health Canada Submission: Similar application targeting Canadian youths, including a two-year antibody response study.
The potential approval could pave the way for increased vaccination efforts in this age group, enhancing public health initiatives.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.